ABSTRACT
Patients with hematological malignancies or recipients of hematopoietic stem cell
transplants may develop myriad pulmonary manifestations, as a complication of either
the disease or the diverse agents used to treat the disease. Clinical, radiographic,
and physiological features of drug-induced and radiation-induced pulmonary injury
are often difficult to distinguish from other causes of pulmonary infiltrates (e.g.,
infections, pulmonary edema, alveolar hemorrhage, etc.). Fiberoptic bronchoscopy with
bronchoalveolar lavage (BAL) is essential to exclude infectious etiologies. In some
cases, surgical lung biopsies are required to establish a specific etiological diagnosis.
This review discusses the myriad causes of lung injury/toxicity that may afflict patients
with hematological malignancies or transplant recipients, and presents diagnostic
and therapeutic approaches.
KEYWORDS
Drug-induced pneumonitis - radiation pneumonitis - chemotherapy-induced lung
REFERENCES
- 1
Limper A H.
Chemotherapy-induced lung disease.
Clin Chest Med.
2004;
25
53-64
- 2
Afessa B.
Pretransplant pulmonary evaluation of the blood and marrow transplant recipient.
Chest.
2005;
128
8-10
- 3
Stiff P J, Unger J M, Forman S J et al..
The value of augmented preparative regimens combined with an autologous bone marrow
transplant for the management of relapsed or refractory Hodgkin disease: a Southwest
Oncology Group phase II trial.
Biol Blood Marrow Transplant.
2003;
9
529-539
- 4
Fryer C J, Hutchinson R J, Krailo M et al..
Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional
radiation in advanced Hodgkin's disease in children: a report from the Children's
Cancer Study Group.
J Clin Oncol.
1990;
8
1971-1980
- 5
Rossi H A, Becker P S, Emmons R V et al..
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem
cell transplantation for patients with non-Hodgkin's lymphoma.
Bone Marrow Transplant.
2003;
31
441-446
- 6
Stuart M J, Chao N S, Horning S J et al..
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed
by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's
disease.
Biol Blood Marrow Transplant.
2001;
7
552-560
- 7
Engelfriet C P, Reesink H W, Brand A et al..
Transfusion-related acute lung injury (TRALI).
Vox Sang.
2001;
81
269-283
- 8
Abratt R P, Onc F R, Morgan G W, Silvestri G, Willcox P.
Pulmonary complications of radiation therapy.
Clin Chest Med.
2004;
25
167-177
- 9 http://www.pneumotox.com Pneumotox® Web site: 1997. Producers: P Foucher-Ph. Camus: Last update: July, 2005
- 10
Bruno B, Souillet G, Bertrand Y, Werck-Gallois M C, So Satta A, Bellon G.
Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children
in a single paediatric centre.
Bone Marrow Transplant.
2004;
34
143-147
- 11
White D A.
Drug-induced pulmonary infection.
Clin Chest Med.
2004;
25
179-188
- 12
Khurshid I, Anderson L C.
Non-infectious pulmonary complications after bone marrow transplantation: thoracic
complications related to bone marrow transplantation.
Postgrad Med J.
2002;
78
257-262
- 13
Franquet T, Muller N L, Lee K S, Gimenez A, Flint J D.
High-resolution CT and pathologic findings of noninfectious pulmonary complications
after hematopoietic stem cell transplantation.
AJR Am J Roentgenol.
2005;
184
629-637
- 14 Plataki M, Bouros D.
Iatrogenic and rare pleural effusion. In: Bouros D Pleural Disorders. New York; Dekker 2004: 897-913
- 15
Zisman D A, McCune W J, Tino G, Lynch J PI.
Drug-induced pneumonitis: the role of methotrexate.
Sarcoidosis Vasc Diffuse Lung Dis.
2001;
18
243-252
- 16
Sleijfer S.
Bleomycin pneumonitis.
Chest.
2001;
120
617-624
- 17
O'Driscoll B R, Hasleton P S, Taylor P M, Poulter L W, Gattamaneni H R, Woodcock A A.
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.
N Engl J Med.
1990;
323
378-382
- 18
Erasmus J J, McAdams H P, Rossi S E.
Drug-induced lung injury.
Semin Roentgenol.
2002;
37
72-81
- 19
Erasmus J J, McAdams H P, Rossi S E.
High-resolution CT of drug-induced lung disease.
Radiol Clin North Am.
2002;
40
61-72
- 20
Cleverley J R, Screaton N J, Hiorns M P, Flint J D, Müller N L.
Drug-induced lung disease: high-resolution CT and histological findings.
Clin Radiol.
2002;
57
292-299
- 21
Mulabecirovic A, Gaulhofer P, Auner H W et al..
Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung
biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic
pneumonitis.
Ann Hematol.
2004;
83
420-422
- 22
Flieder D B, Travis W D.
Pathologic characteristics of drug-induced lung disease.
Clin Chest Med.
2004;
25
37-46
- 23
Bolanos-Meade J, Ioffe O, Hey J C, Vogelsang G B, Akpek G.
Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of
the lung.
Am J Hematol.
2005;
79
132-135
- 24
Kremer J M, Alarcon G S, Weinblatt M E et al..
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated
lung injury in patients with rheumatoid arthritis.
Arthritis Rheum.
1997;
40
1829-1837
- 25
Imokawa S, Colby T V, Leslie K O, Helmers R A.
Methotrexate pneumonitis: review of the literature and histopathological findings
in nine patients.
Eur Respir J.
2000;
15
373-381
- 26
Rossi S E, Erasmus J J, McAdams P, Sporn T A, Goodman P C.
Pulmonary drug toxicity: radiologic and pathologic manifestations.
Radiographics.
2000;
5
1245-1259
- 27
Fuhrman C, Parrot A, Wislez M et al..
Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced
pneumonitis.
Am J Respir Crit Care Med.
2001;
164
1186-1191
- 28
Marzouk K, Saleh S, Kannass M, Sharma O P.
Interferon-induced granulomatous lung disease.
Curr Opin Pulm Med.
2004;
10
435-440
- 29
Berkani K, Bayle J Y, Perol M, Bejui-Thivolet F, Perrot D, Guérin J C.
“Spontaneous” resolution of two severe methotrexate-induced pneumonias.
Rev Pneumol Clin.
2003;
59
301-305
- 30
Fehr T, Jacky E, Bachli E B.
Successful reintroduction of methotrexate after acute, pneumonitis in a patient with
acute lymphoblastic leukemia.
Ann Hematol.
2003;
82
193-196
- 31
Oddo M, Liaudet L, Lepori M, Broccard A F, Schaller M D.
Relapsing acute respiratory failure induced by minocycline.
Chest.
2003;
123
2146-2148
- 32
Baptista J P, Casanova P C, Sousa J P et al..
Acute eosinophilic pneumonia associated with acute respiratory distress syndrome:
case report.
Rev Port Pneumol.
2004;
10
355-364
- 33
Gaensler E A, Carrington C B.
Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative
of pulmonary edema.
AJR Am J Roentgenol.
1977;
128
1-13
- 34
Egerer G, Witzens M, Spaeth A et al..
Successful treatment of bronchiolitis obliterans organizing pneumonia with low-dose
methotrexate in a patient with Hodgkin's disease.
Oncology.
2001;
61
23-27
- 35
Kalambokis G, Stefanou D, Arkoumani E, Kitsanou M, Bourantas K, Tsianos E V.
Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment
with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous
leukemia.
Eur J Haematol.
2004;
73
67-70
- 36
Ferriby D, Stojkovic T.
Bronchiolitis obliterans with organizing pneumonia during interferon β-1a treatment.
Lancet.
2001;
357
751
- 37
Santrach P J, Askin F B, Wells R J, Azizkhan R G, Merten D F.
Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma.
Cancer.
1989;
64
806-811
- 38
Gehl H B, Hauptmann S, Sohn M, Bohndorf K.
Late pulmonary changes following bleomycin administration in computed tomography:
nodular fibrosis mimicking a seminoma metastasis.
Radiologe.
1992;
32
80-82
- 39
Ben Arush M W, Roguin A, Zamir E et al..
Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs
in childhood cancer.
Pediatr Hematol Oncol.
1997;
14
381-386
- 40
Kreisman H, Wolkove N.
Pulmonary toxicity of antineoplastic therapy.
Semin Oncol.
1992;
19
508-520
- 41
Friedberg J W, Neuberg D, Kim H et al..
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of
de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
Cancer.
2003;
98
978-982
- 42
Bredenfeld H, Franklin J, Nogova L et al..
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated
with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine,
prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination
of gemcitabine and bleomycin: a report of the German Hodgkin's lymphoma Study Group.
J Clin Oncol.
2004;
22
2424-2429
- 43
Rubio C, Hill M E, Milan S, O'Brien M ER, Cunningham D.
Idiopathic pneumonia syndrome after high dose chemotherapy for relapsed Hodgkin's
disease.
Br J Cancer.
1997;
75
1044-1048
- 44
Quigley M, Brada M, Heron C, Horwich A.
Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with
non-Hodgkin's lymphoma.
Hematol Oncol.
1988;
6
319-324
- 45
Todd N W, Peters W P, Ost A H, Roggli V L, Piantadosi A C.
Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose
combination chemotherapy and autologous bone marrow transplantation.
Am Rev Respir Dis.
1993;
147
1264-1270
- 46
Colby T V.
Surgical pathology of non-neoplastic lung disease.
Mod Pathol.
2000;
13
343-358
- 47
Huang M S, Colby T V, Goellner J R, Martin W J.
Utility of bronchoalveolar lavage in the diagnosis of drug induced pulmonary toxicity.
Acta Cytol.
1989;
33
533-538
- 48
Maehara K, Shiraki M, Hara I, Koike S, Matsumiya T.
Possible association of drug therapy with pulmonary alveolar proteinosis (PAP) in
patients with malignant haematological disorders.
Jpn J Pharmacol.
1999;
79
285P
- 49
Du E Z, Yung G L, Le D T, Masliah E, Yi E S, Friedman P J.
Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a
lung allograft recipient.
J Thorac Imaging.
2001;
16
307-309
- 50
Kantrow S P, Hackman R C, Boeckh M, Myerson D, Crawford S W.
Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation.
Transplantation.
1997;
63
1079-1086
- 51
Cao T M, Negrin R S, Stockerl-Goldstein K E et al..
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose
chemotherapy and autologous hematopoietic cell transplantation.
Biol Blood Marrow Transplant.
2000;
6
387-394
- 52
Shankar G, Cohen D A.
Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant
radiation conditioning and local cytokine dysregulation in promoting lung inflammation
and fibrosis.
Int J Exp Pathol.
2001;
82
101-113
- 53
Wong R, Rondon G, Saliba R M et al..
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic
stem cell transplantation for high-risk breast cancer.
Bone Marrow Transplant.
2003;
31
1157-1163
- 54
Shapiro C L, Yeap D Y, Godleski J et al..
Drug-related pulmonary toxicity in non-Hodgkin's lymphoma: comparative results with
three different treatment regimens.
Cancer.
1991;
68
699-705
- 55
Moormeier J A, Williams S F, Kaminer L S, Garner M, Bitran J D.
High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients
with refractory malignancies.
J Natl Cancer Inst.
1990;
82
29-34
- 56
Alessandrino E P, Bernasconi P, Colombo A et al..
Pulmonary toxicity following carmustine-based preparative regimens and autologous
peripheral blood progenitor cell transplantation in hematological malignancies.
Bone Marrow Transplant.
2000;
25
309-313
- 57
Brice P, Tredaniel J, Monsuez J J et al..
Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in
favorable Hodgkin's disease.
Ann Oncol.
1991;
2(Suppl 2)
73-76
- 58
Kalaycioglu M, Kavuru M, Tuason L, Bolwell B.
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy
containing carmustine.
Chest.
1995;
107
482-487
- 59
Bhalla K S, Wilczynski S W, Abushamaa A M et al..
Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy
with autologous hematopoietic support.
Am J Respir Crit Care Med.
2000;
161
17-25
- 60
Maher J, Daly P A.
Severe bleomycin lung toxicity: reversal with high dose corticosteroids.
Thorax.
1993;
48
92-94
- 61
Segura A, Yuste A, Cercos A et al..
Pulmonary fibrosis induced by cyclophosphamide.
Ann Pharmacother.
2001;
35
894-897
- 62
Lindell R M, Hartman T E.
Chest imaging in iatrogenic respiratory disease.
Clin Chest Med.
2004;
25
15-24
- 63
Dai M S, Lee S C, Ho C L, Chen Y C, Kao W Y, Chao T Y.
Impact of open lung biopsy for undiagnosed pulmonary infiltrates in patients with
hematological malignancies.
Am J Hematol.
2001;
68
87-90
- 64
Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J.
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach
to diagnosis and treatment.
Bone Marrow Transplant.
1997;
20
1063-1067
- 65
White D A, Wong P W, Downey R.
The utility of open lung biopsy in patients with hematologic malignancies.
Am J Respir Crit Care Med.
2000;
161
723-729
- 66
Richter J E, Hastedt R, Dalton J F, Marshall D, Raymond L W.
Pulmonary toxicity of bischloronitrosourea: report of a case with transient response
to corticosteroid therapy.
Cancer.
1979;
43
1607-1612
- 67
White D A, Orenstein M, Godwin T A, Stover D E.
Chemotherapy-associated pulmonary toxic reactions during treatment for breast cancer.
Arch Intern Med.
1984;
144
953-956
- 68
Zappasodi P, Vitulo P, Volpini E, Castagnola C, Nascimbene C, Corso A.
Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated
lung injury.
Ann Hematol.
2002;
81
347-349
- 69
Bell M R, Meredith D J, Gill P G.
Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced
pulmonary toxicity.
Aust NZJ Med.
1985;
15
235-240
- 70
Lind P A, Marks L B, Jamieson T A et al..
Predictors for pneumonitis during locoregional radiotherapy in high-risk patients
with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
Cancer.
2002;
94
2821-2829
- 71
Wolkowicz J, Sturgeon J, Rawji M, Chan C K.
Bleomycin-induced pulmonary function abnormalities.
Chest.
1992;
101
97-101
- 72
Tucker A S, Newman A J, Alvorado C.
Pulmonary, pleural and thoracic changes complicating chemotherapy.
Radiology.
1977;
125
805-809
- 73
Malik S W, Myers J L, DeRemee R A, Specks U.
Lung toxicity associated with cyclophosphamide use: two distinct patterns.
Am J Respir Crit Care Med.
1996;
154
1851-1856
- 74
[No authors listed.] .
The Hamman-Rich syndrome following treatment of lymphoma with chlorambucil.
J La State Med Soc.
1975;
127
311-315
- 75
Bedrossian C WM, Miller W C, Luna M A.
Methotrexate-induced diffuse interstitial pulmonary fibrosis.
South Med J.
1979;
72
313-318
- 76
Attar E C, Ervin T, Janicek M, Deykin A, Godleski J.
Acute interstitial pneumonitis related to gemcitabine.
J Clin Oncol.
2000;
18
697-698
- 77
Hirschi S, Lange F, Battesti J P, Lebargy F.
Pulmonary sarcoid-like granulomatosis associated with Hodgkin's disease and complicated
by bleomycin-induced pulmonary nodules.
Ann Med Interne (Paris).
1998;
149
164-166
- 78
Kornacker M, Kraemer A, Leo E, Ho A D.
Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report
of two cases.
Ann Hematol.
2002;
81
103-105
- 79
Vandenplas O, Hanston P, Dive A, Mahieu P.
Fulminant pulmonary edema following intravenous administration of radiographic media.
Acta Clin Belg.
1990;
45
334-339
- 80
Vaylet F, Plotton C, Algayres J P, Verkindre C, L'Her P.
Oedème aigu du poumon après vinorelbine.
Presse Med.
1996;
25
1259-1260
- 81
Reed C R, Glauser F L.
Drug-induced non cardiogenic pulmonary edema.
Chest.
1991;
100
1120-1124
- 82
Briasoulis E, Pavlidis N.
Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer
therapy.
Oncologist.
2001;
6
153-161
- 83
Briasoulis E, Froudarakis M, Milionis H, Peponis I, Constantopoulos S, Pavlidis N.
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel
combination with granulocyte colony-stimulating factor support.
Respiration.
2000;
67
680-683
- 84
Schwarz M I, Fontenot A P.
Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis.
Clin Chest Med.
2004;
25
133-140
- 85
Corso S, Vukelja S J, Wiener D, Baker W J.
Diffuse alveolar hemorrhage following autologous bone marrow infusion.
Bone Marrow Transplant.
1993;
12
301-303
- 86
Srivastava A, Gottlieb D, Bradstock K F.
Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone
marrow transplantation.
Bone Marrow Transplant.
1995;
15
863-867
- 87
Glasier C M, Siegel M J.
Multiple pulmonary nodules: unusual manifestation of bleomycin toxicity.
AJR Am J Roentgenol.
1981;
137
155-156
- 88
Franchi F, Seminara P, Gualdi G F.
Lung pseudometastases due to vinblastine toxicity.
Klin Wochenschr.
1984;
62
1047-1048
- 89
Scharstein R, Johnson J F, Cook B A, Stephenson S R.
Bleomycin nodules mimicking metastatic osteogenic sarcoma.
Am J Pediatr Hematol Oncol.
1987;
9
219-221
- 90
Garg S, Garg M S, Basmaji N.
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity:
case report and review of literature.
Am J Hematol.
2002;
70
241-245
- 91
Gulbahce H E, Manivel J C, Jessurun J.
Pulmonary cytolytic thrombi: a previously unrecognized complication of bone marrow
transplantation.
Am J Surg Pathol.
2000;
24
1147-1152
- 92
Gulbahce H E, Pambuccian S E, Jessurun J et al..
Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic
diagnosis on patient management and prognosis.
Am J Clin Pathol.
2004;
121
205-210
- 93
White D A, Schwartzberg L S, Kris M G, Bosl G J.
Acute chest pain syndrome during bleomycin infusions.
Cancer.
1987;
59
1582-1585
- 94
Hudson M M, Weinstein H J, Donaldson S S et al..
Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
J Clin Oncol.
1993;
11
1080-1084
- 95
Yano S, Shimada K.
Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient
with lung cancer.
Jpn Circ J.
1996;
60
185-188
- 96
Urban C, Nirenberg A, Caparros B, Anac S, Cacavio A, Rosen G.
Chemical pleuritis as the cause of acute chest pain following high-dose methotrexate
treatment.
Cancer.
1983;
51
34-37
- 97
Brandt R R, Dunn W F, Ory S J.
Dextran 70 embolization: another cause of pulmonary hemorrhage, coagulopathy, and
rhabdomyolysis.
Chest.
1993;
104
631-633
- 98
Rubin R L.
Drug-induced lupus.
Toxicology.
2005;
209
135-147
- 99
Rivera M P, Kris M G, Gralla R J, White D A.
Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy.
Am J Clin Oncol.
1995;
18
245-250
- 100
Dillman R O.
Infusion reactions associated with the therapeutic use of monoclonal antibodies in
the treatment of malignancy.
Cancer Metastasis Rev.
1999;
18
465-471
- 101
Benekli M, Anderson B, Wentling D, Bernstein S, Czuczman M, McCarthy P.
Severe respiratory depression after dimethylsulphoxide-containing autologous stem
cell infusion in a patient with AL amyloidosis.
Bone Marrow Transplant.
2000;
25
1299-1301
- 102
Shanholtz C.
Acute life-threatening toxicity of cancer treatment.
Crit Care Clin.
2001;
17
483-502
- 103
Ferrucci P F, Martinoni A, Cocorocchio E.
Evaluation of acute toxicities associated with autologous peripheral blood progenitor
cell reinfusion in patients undergoing high-dose chemotherapy.
Bone Marrow Tranplant.
2002;
25
173-177
- 104
Mills B A, Roberts R W.
Cyclophosphamide-induced cardiomyopathy.
Cancer.
1979;
43
2223-2226
- 105
Manthorpe R, Svensson O.
Cardiomyopathy following intravenous cyclophosphamide therapy in a patient with Wegener's
granulomatosis.
Clin Exp Rheumatol.
1996;
14
702-703
- 106
Hayek E R, Speakman E, Rehmus E.
Acute doxorubicin cardiotoxicity.
N Engl J Med.
2005;
352
2456-2457
- 107
Levine S J, Walsh T J, Martinez A, Eichacker P Q, Lopez-Berestein G, Natanson C.
Cardiopulmonary toxicity after liposomal amphotericin B infusion.
Ann Intern Med.
1991;
114
664-666
- 108
Vincent L, Lamrini R, Pommier P, Martel I, Helfre S, Carrie C.
Arrêt cardiaque et vinorelbine? A propos d'un cas et revue de la littérature.
Rev Pneumol Clin.
1997;
53
360-361
- 109
Prosnitz R G, Chen Y H, Marks L B.
Cardiac toxicity following thoracic radiation.
Semin Oncol.
2005;
32
S71-S80
- 110
Heidenreich P A, Hancock S L, Lee B K, Mariscal C S, Schnittger I.
Asymptomatic cardiac disease following mediastinal irradiation.
J Am Coll Cardiol.
2003;
42
743-749
- 111 Camus P.
Drug-induced pleural disease. In: Bouros D Pleural Disorders. York; Dekker 2004: 317-352
- 112
Hamada K, Nagai S, Kitaichi M et al..
Cyclophosphamide-induced late-onset lung disease.
Intern Med.
2003;
42
82-87
- 113
Jensen B V, Carlsen N LT, Groth S, Nissen N I.
Late effects on pulmonary function of mantle-field irradiation, chemotherapy or combined
modality therapy for Hodgkin's disease.
Eur J Haematol.
1990;
44
165-171
- 114
Fanfulla F, Locatelli F, Zoia M C et al..
Pulmonary complications and respiratory function changes after bone marrow transplantation
in children.
Eur Respir J.
1997;
10
2301-2306
- 115
Hoppe R T.
Hodgkin's disease: complications of therapy and excess mortality.
Ann Oncol.
1997;
8
115-118
- 116
van Leeuwen F E, Klokman W J, Stovall M et al..
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.
J Natl Cancer Inst.
1995;
87
1530-1537
- 117
Travis L B, Gospodarowicz M, Curtis R E et al..
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.
J Natl Cancer Inst.
2002;
94
182-192
- 118
Gilbert E S, Stovall M, Gospodarowicz M et al..
Lung cancer after treatment for Hodgkin's disease: focus on radiation effects.
Radiat Res.
2003;
159
161-173
- 119
Swerdlow A J, Schoemaker M J, Allerton R et al..
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to
treatment.
J Clin Oncol.
2001;
19
1610-1618
- 120
Zablotska L B, Angevine A H, Neugut A I.
Therapy-induced thoracic malignancies.
Clin Chest Med.
2004;
25
217-224
- 121
Tolar J, Coad J E, Ramsay N KC, Peters C, Davies S M.
Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation.
Bone Marrow Transplant.
2001;
28
808-810
- 122
Wright D G, Robichaud K J, Pizzo P A, Deiseroth A B.
Lethal pulmonary reactions associated with the combined use of amphotericin B and
leukocyte transfusions.
N Engl J Med.
1981;
304
1185-1189
- 123
Arning M, Heer-Sonderhoff A H, Wehmeir A, Schneider W.
Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with
acute leukemia.
Eur J Clin Microbiol Infect Dis.
1995;
14
41-43
- 124
Garnacho-Montero J, Ortiz-Leyba C, Garcia-Garmenda J L, Jiminez-Jiminez F J.
Life-threatening adverse event after amphotericin B lipid complex treatment in a patient
treated previously with amphotericin B deoxycholate.
Clin Infect Dis.
1998;
26
1016
- 125
Spitzer T R, Creger R J, Fox R M, Lazarus H M.
Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic
fever.
Pharmatherapeutica.
1989;
5
305-311
- 126
Lowery M M, Greenberger P A.
Amphotericin-induced stridor: a review of stridor, amphotericin preparations, and
their immunoregulatory effects.
Ann Allergy Asthma Immunol.
2003;
91
460-466
- 127
Collazos J, Martinez E, Mayo J, Ibarra S.
Pulmonary reactions during treatment with amphotericin B: review of published cases
and guidelines for management.
Clin Infect Dis.
2001;
33
E75-E82
- 128
Maillard N, Foucher P, Caillot D, Durand C, Sgro C, Camus P.
Transient pulmonary infiltrates during treatment with anti-thymocyte globulin.
Respiration.
1999;
66
279-282
- 129
Castaigne S, Chomienne C, Daniel M T et al..
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia,
I: Clinical results.
Blood.
1990;
76
1704-1709
- 130
Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell Jr R P.
The “retinoic acid syndrome” in acute promyelocytic leukemia.
Ann Intern Med.
1992;
117
292-296
- 131
Nicolls M R, Terada L S, Tuder R M, Priniville S A, Schwarz M I.
Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic
acid syndrome.
Am J Respir Crit Care Med.
1998;
158
1302-1305
- 132
Camacho L H, Soignet S L, Chanel S et al..
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia
treated with arsenic trioxide.
J Clin Oncol.
2000;
18
2620-2625
- 133
Davis B A, Cervi P, Amin Z, Moshi G, Shaw P, Porter J.
Retinoic acid syndrome: pulmonary computed tomography (CT) findings.
Leuk Lymphoma.
1996;
23
113-117
- 134
Maloisel F, Petit T, Kessler R, Oberling F.
Cytologic examination of broncho-alveolar fluid during the retinoic acid syndrome.
Eur J Haematol.
1996;
56
319-320
- 135
Wiley J S, Firkin F C.
Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic
acid treatment of acute promyelocytic leukemia.
Leukemia.
1995;
9
774-778
- 136
Goldschmidt N, Gural A, BenYehuda D.
Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating
induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia.
Leuk Lymphoma.
2003;
44
1433-1437
- 137
Weiss R B, Poster D S, Penta J S.
The nitrosoureas and pulmonary toxicity.
Cancer Treat Rev.
1981;
8
111-125
- 138
Smith A C.
The pulmonary toxicity of nitrosoureas.
1989;
41
443-460
- 139
Massin F, Coudert B, Foucher P et al..
Nitrosourea-induced pneumonitis.
Rev Mal Respir.
1992;
9
575-582
- 140
Aronin P A, Mahaley M SJ, Rudnick S A et al..
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment
of risk factors.
N Engl J Med.
1980;
303
183-188
- 141
Tucci E, Verdiani P, Di Carlo S, Sforza V.
Lomustine (CCNU)-induced pulmonary fibrosis.
Tumori.
1986;
72
95-98
- 142
Mitsudo S M, Greenwald E S, Banerji B, Koss L G.
BCNU (1 3-bis-(2-chloroethyl)-1-nitrosourea) lung: drug-induced pulmonary changes.
Cancer.
1984;
54
751-755
- 143
Lohani S, O'Driscoll B R, Woodcock A A.
25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.
Chest.
2004;
126
1007
- 144
Ishizuka M, Takayama H, Takeuchi T, Umezawa H.
Activity and toxicity of bleomycin.
J Antibiot (Tokyo).
1967;
20
15-24
- 145
Balikian J P, Jochelson M S, Bauer K A et al..
Pulmonary complications of chemotherapy regimens containing bleomycin.
AJR Am J Roentgenol.
1982;
139
455-461
- 146
Trump D L, Bartel E, Pozniak M.
Nodular pneumonitis after chemotherapy for germ cell tumors.
Ann Intern Med.
1988;
109
431-432
- 147
Iacovino J R, Leitner J, Abbas A K, Lokich J J, Snider G L.
Fatal pulmonary reaction from low doses of bleomycin: an idiosyncratic tissue response.
JAMA.
1976;
235
1253-1255
- 148
Bechard D E, Fairman R P, DeBlois G G, Via C T.
Fatal pulmonary fibrosis from low-dose bleomycin therapy.
South Med J.
1987;
80
646-649
- 149
Einhorn L, Krause M, Hornbarck N, Furnas B.
Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer.
Cancer.
1976;
37
2414-2416
- 150
Krous H F, Hamlin W B.
Pulmonary toxicity due to bleomycin: report of a case.
Arch Pathol.
1973;
95
407-410
- 151
Toledo C H, Ross W E, Hood C I, Block E R.
Potentiation of bleomycin toxicity by oxygen.
Cancer Treat Rep.
1982;
66
359-362
- 152
White D A, Stover D E.
Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids.
Chest.
1984;
86
723-728
- 153
Simpson A B, Paul J, Graham J, Kaye S B.
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients
with germ cell tumours.
Br J Cancer.
1998;
78
1061-1066
- 154
Kawai K, Akaza H.
Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer.
Expert Opin Drug Saf.
2003;
2
587-596
- 155
Bargon G.
Drug-induced changes in the lungs.
Rontgenblatter.
1984;
37
261-265
- 156
Bellamy E A, Husband J E, Blaquiere R M, Law M R.
Bleomycin related lung damage: CT evidence.
Radiology.
1985;
156
155-158
- 157
Kuhlman J E.
The role of chest computed tomography in the diagnosis of drug-related reactions.
J Thorac Imaging.
1991;
6
52-61
- 158
Daba M H, El-Tahir K E, Al-Arifi M N, Gubara O A.
Drug-induced pulmonary fibrosis.
Saudi Med J.
2004;
25
700-706
- 159
Bellamy E A, Nicholas D, Husband J E.
Quantitative assessment of lung damage due to bleomycin using computed tomography.
Br J Radiol.
1987;
60
1205-1209
- 160
Mills P, Husband J.
Computed tomography of pulmonary bleomycin toxicity.
Semin Ultrasound CT MR.
1990;
11
417-422
- 161
Rimmer M J, Dixon A K, Flower C DR, Sikora K.
Bleomycin lung: computed tomographic observations.
Br J Radiol.
1985;
58
1041-1045
- 162
White D A, Kris M G, Stover D E.
Bronchoalveolar lavage cell populations in bleomycin lung toxicity.
Thorax.
1987;
42
551-552
- 163
Yousem S A, Lifson J D, Colby T V.
Chemotherapy-induced eosinophilic pneumonia: relation to bleomycin.
Chest.
1985;
88
103-106
- 164
O'Neill T J, Kardinal C G, Tierney L M.
Reversible interstitial pneumonitis associated with low-dose bleomycin.
Chest.
1975;
68
265-267
- 165
Lewis B M, Izbicki R.
Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective
and potentially misleading.
JAMA.
1980;
243
347-351
- 166
Schaaf W, Vogel H, Kresuer E, Demandt M.
Postoperative ARDS as a possible consequence of bleomycin therapy performed 7 years
ago: a case study.
Anästhesiol Intensivmed.
2003;
44
436-440
- 167
Kopko P M, Popovsky M A.
Pulmonary injury from transfusion-related acute lung injury.
Clin Chest Med.
2004;
25
105-113
- 168
Kopko P M, Marshall C S, MacKenzie M R, Holland P V, Popovsky M A.
Transfusion-related acute lung injury. Report of a clinical look-back investigation.
JAMA.
2002;
287
1968-1971
- 169
Popovsky M A.
Transfusion and lung injury.
Transfus Clin Biol.
2001;
8
272-277
- 170
Gajic O, Moore S B.
Transfusion-related acute lung injury.
Mayo Clin Proc.
2005;
80
766-770
- 171
Carilli A D, Ramamurthy M V, Chang Y-S, Shin D, Sehti V.
Noncardiogenic pulmonary edema following blood transfusion.
Chest.
1978;
74
310-312
- 172
Popovsky M A.
Transfusion and the lung: circulatory overload and acute lung injury.
Vox Sang.
2004;
87
62-65
- 173
Dubois M, Lotze M T, Diamond W J, Kim Y D, Flye M W, MacNamara T E.
Pulmonary shunting during leukoagglutinin-induced noncardiac pulmonary edema.
JAMA.
1980;
244
2186-2189
- 174
Yost C S, Matthay M A, Gropper M A.
Etiology of acute pulmonary edema during liver transplantation.
Chest.
2001;
119
219-223
- 175
Levy G J, Shabot M M, Hart M E, Mya W W, Goldfinger D.
Tranfusion-associated noncardiogenic pulmonary edema: report of a case and a warning
regarding treatment.
Transfusion.
1986;
26
278-281
- 176
Massin F, Fur A, Reybet-Degat O, Camus P, Jeannin L.
Busulfan-induced pneumonitis.
Rev Mal Respir.
1987;
4
3-10
- 177
Nelson B M, Andrews G A.
Breast cancer and cytologic dysplasia in many organs after Busulfan.
Am J Clin Pathol.
1964;
42
37-44
- 178
[No authors listed.] .
Case records of the Massachusetts General Hospital: case 25-1997.
N Engl J Med.
1997;
337
480-489
- 179
Kirschner R H, Esterly J R.
Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.
Cancer.
1971;
27
1074-1080
- 180
Aymard J P, Gyger M, Lavallee R, Legresley L P, Desy M.
A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia:
a peculiar pathologic aspect of busulfan lung?.
Cancer.
1984;
53
954-956
- 181
Littler W A, Ogilvie C.
Lung function in patients receiving busulphan.
Br Med J.
1970;
ii
530-532
- 182
Giles F J, Smith M P, Goldstone A H.
Chlorambucil lung toxicity.
Acta Haematol.
1990;
83
156-158
- 183
Mohr M, Kingreen D, Rühl H, Huhn D.
Interstitial lung disease: an underdiagnosed side-effect of chlorambucil?.
Ann Hematol.
1993;
67
305-307
- 184
Khong H T, McCarthy J.
Chlorambucil-induced pulmonary disease: a case report and review of the literature.
Ann Hematol.
1998;
77
85-87
- 185
Ruiz-Argüelles G J, Arizpe-Bravo D, Sanchez-Sosa S, Rojas-Ortega S, Moreno-Ford V,
Ruiz-Argüelles A.
Fatal G-CSF-induced pulmonary toxicity.
Am J Hematol.
1999;
60
82-83
- 186
Lei K IK, Leung W T, Johnson P J.
Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating
factor during BACOP chemotherapy for agressive non-Hodgkin's lymphoma.
Br J Cancer.
1994;
70
1009-1013
- 187
Yokose N, Ogata K, Tamura H et al..
Pulmonary toxicity after granulocyte colony stimulating factor-combined chemotherapy
for non-Hodgkin's lymphoma.
Br J Cancer.
1998;
77
2286-2290
- 188
Saxman S B, Nichols C R, Einhorn L H.
Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin
with and without granulocyte colony stimulating factor.
Chest.
1997;
111
657-660
- 189
Gatti E, Scagliotti G V, Ferrari G et al..
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage
colony-stimulating factor.
Eur Respir J.
1995;
8
1566-1571
- 190
Philippe B, Couderc L J, Balloul-Delclaux E, Janvier M, Caubarrère I.
Pulmonary toxicity of chemotherapy and GM-CSF.
Respir Med.
1994;
88
715
- 191
Sorhage F, Stover D E, Mortazavi A.
Unusual etiology of cough in a woman with asthma.
Chest.
1996;
110
852-854
- 192
Taillé C, Fartoukh M, Houël R, Kobeiter H, Rémy P, Lemaire F.
Spontaneous hemomediastinum complicating steroid-induced mediastinal lipomatosis.
Chest.
2001;
120
311-313
- 193
Decramer M, de Bock V, Dom R.
Functional and histologic picture of steroid-induced myopathy in chronic obstructive
pulmonary disease.
Am J Respir Crit Care Med.
1996;
153
1958-1964
- 194
Similowski T, Strauss C.
Iatrogenic-induced dysfunction of the neuromuscular respiratory system.
Clin Chest Med.
2004;
25
155-166
- 195
Kilpiö K, Hannuksela M.
Corticosteroid allergy in asthma.
Allergy.
2003;
58
1131-1135
- 196
Lionakis M S, Kontoyiannis D P.
Glucocorticoids and invasive fungal infections.
Lancet.
2003;
362
1828-1838
- 197
Wolley J, Collett J, Goldstein D.
Diffuse alveolar damage following a single administration of a cyclophosphamide containing
chemotherapy regimen.
Aust NZ J Med.
1997;
27
605-606
- 198
Cuguillière A, Bérard H, N'Guyen G.
Pneumopathie interstitielle liée au cyclophosphamide.
Rev Pneumol Clin.
1999;
55
100-104
- 199
Burke D A, Stoddart J C, Ward M K, Simpson C GB.
Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide.
Br Med J.
1982;
285
696
- 200
Abdel Karim F W, Ayash R E, Allam C, Salem P A.
Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide.
Oncology.
1983;
40
174-176
- 201
Topilow A A, Rothenberg S P, Cottrell T S.
Interstitial pneumonia after prolonged treatment with cyclophosphamide.
Am Rev Respir Dis.
1973;
108
114-117
- 202
Alvarado C S, Boat T F, Newman A J.
Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.
J Pediatr.
1978;
92
443-446
- 203
Kulke M H, Vance E A.
Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer.
Clin Infect Dis.
1997;
25
215-218
- 204
[No authors listed.] .
Case records of the Massachusetts General Hospital: case 35-1984.
N Engl J Med.
1984;
311
585-593
- 205
Haupt H M, Hutchins G M, Moore G W.
Ara-C lung: non-cardiogenic pulmonary edema complicating cytosine arabinoside therapy
of leukaemia.
Am J Med.
1981;
70
256-261
- 206
Jehn U, Göldel N, Rienmüller R, Wilmanns W.
Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment
for relapsed acute leukemia.
Med Oncol Tumor Pharmacother.
1988;
5
41-47
- 207
Shearer P, Katz J, Bozeman P et al..
Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in
five pediatric patients with relapsed acute myelogenous leukemia.
Cancer.
1994;
74
1953-1958
- 208
Andersson B S, Luna B S, Yee C, Hui K K, Keating M J, McCreadie K B.
Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute
leukemia.
Cancer.
1990;
65
1079-1084
- 209
Tenenbein M, Adamson I YR.
Desferrioxamine and pulmonary injury.
Lancet.
1992;
340
428-429
- 210
Freedman M H, Grisaru D, Olivieri N, McLusky I, Thorner P S.
Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine
infusions.
Am J Dis Child.
1990;
144
565-569
- 211
Miller K B, Rosenwasser L J, Bessette J AM, Beer D J, Rocklin R E.
Rapid desensitization for desferrioxamine anaphylactic reaction.
Lancet.
1981;
1
1059
- 212
Fassas A, Gojo I, Rapoport A et al..
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide,
cisplatin) chemotherapy.
Bone Marrow Transplant.
2001;
28
399-403
- 213
Solal-Celigny P, Brice P, Brousse N et al..
Phase II trial of fludarabine monophosphate as first-line treatment in patients with
advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes
de l'Adulte.
J Clin Oncol.
1996;
14
514-519
- 214
Cervantes F, Salgado C, Montserrat E, Rozman C.
Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
Lancet.
1990;
336
1130
- 215
Helman D LJ, Byrd J C, Ales N C, Shorr A F.
Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative
syndromes.
Chest.
2002;
122
785-790
- 216
Trojan A, Meier R, Licht A, Taverna C.
Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's
lymphoma.
Ann Hematol.
2002;
81
535-537
- 217
Ales N C, Helman D L, Shorr A F, Byrd J C.
Fludarabine associated pulmonary toxicity in chronic in lymphoproliferative disoders:
a case series.
Blood.
2000;
96
756a-757a
- 218
Pavlakis N, Bell D R, Millward M J, Levi J A.
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Cancer.
1997;
80
286-291
- 219
Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer J P.
Gemcitabine-induced severe pulmonary toxicity.
Fundam Clin Pharmacol.
2004;
18
85-91
- 220
Maniwa K, Tanaka E, Inoue T et al..
An autopsy case of acute pulmonary toxicity associated with gemcitabine.
Intern Med.
2003;
42
1022-1025
- 221
Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera P L.
Diffuse alveolar damage in a patient treated with gemcitabine.
Eur Respir J.
1998;
11
504-506
- 222
Sauer-Heilborn A, Kath R, Schneider C P, Hoeffken K.
Severe non-haematological toxicity after treatment with gemcitabine.
J Cancer Res Clin Oncol.
1999;
125
637-640
- 223
Desramé J, Duvic C, Bredin C et al..
Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six
cases and review of the literature.
Rev Med Interne.
2005;
26
179-188
- 224
Schwonzen M, Spangenberger H, Spengler M.
Hydroxyurea-induced pneumonitis.
Med Klin (Munich).
2003;
98
394-397
- 225
Antoniou K M, Ferdoutsis E, Bouros D.
Interferons and their application in the diseases of the lung.
Chest.
2003;
123
209-216
- 226
Ramos-Casals M, Mana J, Nardi N et al..
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.
Medicine (Baltimore).
2005;
84
69-80
- 227
Ishizaki T, Sasaki F, Ameshima S et al..
Pneumonitis during interferon and/or herbal drug therapy in patients with chronic
active hepatitis.
Eur Respir J.
1996;
9
2691-2696
- 228
Moriya K, Yasuda K, Koike K et al..
Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis
C.
J Gastroenterol.
1994;
29
514-517
- 229
Anderson P, Höglund M, Rödjer S.
Pulmonary side effects of interferon-α therapy in patients with hematological malignancies.
Am J Hematol.
2003;
73
54-58
- 230
Kamisako T, Adachi Y, Chihara J, Yamamoto T.
Interstitial pneumonitis and interferon-alfa.
BMJ.
1993;
306
896
- 231
Hoffman S D, Hammadeh R, Shah N.
Eosinophilic pneumonitis secondary to pegylated interferon alpha-2b and/or ribavirin.
Am J Gastroenterol.
2003;
98
S152
- 232
Ogata K, Koga T, Yagawa K.
Interferon-related bronchiolitis obliterans organizing pneumonia.
Chest.
1994;
106
612-613
- 233
Kumar K S, Russo M W, Borczuk A C.
Significant pulmonary toxicity associated with interferon and ribavirin therapy for
hepatitis C.
Am J Gastroenterol.
2002;
97
2432-2440
- 234
Kumar K S, Russo M W, Borczuk A C et al..
Significant pulmonary toxicity associated with interferon and ribavirin therapy for
hepatitis C.
Am J Gastroenterol.
2002;
97
2432-2440
- 235
Pileire G, Leclerc P, Hermant P, Meeus E, Camus P.
Toux chronique isolée pendant un traitement par interféron.
Presse Med.
1999;
28
913
- 236
Krasnowska M, Malolepszy J, Liebhart E.
Interferon as a bronchospastic factor in patients with bronchial asthma.
Pneumonol Alergol Pol.
1992;
60
22-25
- 237
Takeda A, Ikegame K, Kimura Y, Ogawa H, Kanazawa S, Nakamura H.
Pleural effusion during interferon treatment for chronic hepatitis C.
Hepatogastroenterology.
2000;
47
1431-1435
- 238
Fruehauf S, Steiger S, Topaly J, Ho A D.
Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous
leukemia.
Ann Hematol.
2001;
80
308-310
- 239
Price E J, Venables P J.
Drug-induced lupus.
Drug Saf.
1995;
12
283-290
- 240
Shaw E G, Deming R L, Creagan E T et al..
Pilot study of human recombinant interferon gamma and accelerated hyperfractionated
thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell
lung cancer.
Int J Radiat Oncol Biol Phys.
1995;
31
827-831
- 241
Honoré I, Nunes H, Groussard O et al..
Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis.
Am J Respir Crit Care Med.
2003;
167
953-957
- 242
Bergeron A, Bergot E, Vilela G et al..
Hypersensitivity pneumonitis related to imatinib mesylate.
J Clin Oncol.
2002;
20
4271-4272
- 243
Yokoyama T, Miyazawa K, Kurakawa E et al..
Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates
alveolar destruction and fibrosis with eosinophilic infiltration.
Leukemia.
2004;
18
645-646
- 244
Ma C X, Hobday T J, Jett J R.
Imatinib mesylate-induced interstitial pneumonitis.
Mayo Clin Proc.
2003;
78
1578-1579
- 245
Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg D A.
Imatinib-associated pulmonary alveolar proteinosis.
Am J Med.
2003;
115
674
- 246
Taetle R, Dickman P S, Feldman P S.
Pulmonary histopathologic changes associated with melphalan therapy.
Cancer.
1978;
42
1239-1245
- 247
Mufti G J, Hamblin T J, Gordon J.
Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma.
Acta Haematol.
1983;
69
140-141
- 248
Lioté H, Gauthier J F, Prier A, Gauthier-Rahman S, Kaplan G, Akoun G.
Acute, reversible, interstitial pneumopathy induced by melphalan.
Rev Mal Respir.
1989;
6
461-464
- 249
Akasheh M S, Freytes C O, Vesole D H.
Melphalan-associated pulmonary toxicity following high-dose therapy with autologous
hematopoietic stem cell transplantation.
Bone Marrow Transplant.
2000;
26
1107-1109
- 250
Major P P, Laurin S, Bettez P.
Pulmonary fibrosis following therapy with melphalan: report of two cases.
Can Med Assoc J.
1980;
123
197-202
- 251
Clarysse A M, Cathey W J, Cartwright G E, Wintrobe M M.
Pulmonary disease complicating intermittent therapy with methotrexate.
JAMA.
1969;
209
1861-1864
- 252
Massin F, Coudert B, Marot J P, Foucher P, Camus P, Jeannin L.
Methotrexate pneumonitis.
Rev Mal Respir.
1990;
7
5-15
- 253
Kremer J M, Joong K L.
The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid
arthritis.
Arthritis Rheum.
1986;
29
822-831
- 254
van der Veen M J, Dekker J J, Dinant H J, Van Soesbergen R M, Bijlsma J WJ.
Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid
arthritis.
J Rheumatol.
1995;
22
1766-1768
- 255
Renaudier P, Chabot F, Ferry R et al..
Pneumopathies du méthotrexate survenant dans le cadre du traitement des lymphomes
non hodkiniens par le protocole m-BACOD.
Bull Cancer.
1995;
82
149-154
- 256
Pourel J, Guillemin F, Fener P, Webanck L, Bene M-C, Delorme N.
Delayed methotrexate pneumonitis in rheumatoid arthritis.
J Rheumatol.
1991;
18
303-304
- 257
Everts C S, Wescott J L, Bragg D G.
Methotrexate therapy and pulmonary disease.
Radiology.
1973;
107
539-543
- 258
Akoun G M, Mayaud C M, Touboul J L, Denis M F, Milleron B J, Perrot B J.
Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease.
Thorax.
1987;
42
652-655
- 259
White D A, Rankin J A, Stover D E, Gellene R A, Gupta S.
Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder.
Am Rev Respir Dis.
1989;
139
18-21
- 260
Imokawa S, Sato A, Hayakawa H, Toyoshima M, Taniguchi M, Chida K.
Possible involvement of an environmental agent in the development of acute eosinophilic
pneumonia.
Ann Allergy Asthma Immunol.
1996;
76
419-422
- 261
Logan P M, Primack S L, Staples C, Miller R R, Müller N L.
Acute lung disease in the immunocompromised host: diagnostic accuracy of the chest
radiograph.
Chest.
1995;
108
1283-1287
- 262
Kane G C, Troshinsky M B, Peters S P, Israel H L.
Pneumocystis carinii pneumonia associated with weekly methotrexate: cumulative dose of methotrexate and
low CD4 cell count may predict this complication.
Respir Med.
1993;
87
153-155
- 263
Dai M S, Ho C L, Chen Y C, Kao W Y, Chao T Y.
Acute respiratory distress syndrome following intrathecal methotrexate administration:
a case report and review of literature.
Ann Hematol.
2000;
79
696-699
- 264
Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross W L.
Sustained cough in methotrexate therapy for rheumatoid arthritis.
Clin Rheumatol.
1996;
15
277-282
- 265
Newman E D, Harrington T M.
Fatal methotrexate pneumonitis in rheumatoid arthritis.
Arthritis Rheum.
1988;
31
1585-1586
- 266
Cottin V, Tébib J, Massonnet B, Souquet P J, Bernard J-P.
Pulmonary function in patients receiving long-term low-dose methotrexate.
Chest.
1996;
109
933-938
- 267
Mahmood T, Mudad R.
Pulmonary toxicity secondary to procarbazine.
Am J Clin Oncol.
2002;
25
187-188
- 268
Duggan D B, Petroni G R, Johnson J L et al..
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's
disease: report of an intergroup trial.
J Clin Oncol.
2003;
21
607-614
- 269
Jones S E, Moore M, Blank N, Castellino R A.
Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary
reaction.
Cancer.
1972;
29
498-500
- 270
Ecker M D, Jay B, Keohane M F.
Procarbazine lung.
AJR Am J Roentgenol.
1978;
131
527-528
- 271
Horton L WL, Chappell A G, Powell D EB.
Diffuse interstitial pulmonary fibrosis complicating Hodgkin's disease.
Br J Dis Chest.
1977;
71
44-48
- 272
Rosenow E C.
Chemotherapeutic drug-induced pulmonary disease.
Respir Med.
1980;
2
89-96
- 273
Cook R C, Connors J M, Gascoyne R D, Fradet G, Levy R D.
Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal
antibody after lung transplantation.
Lancet.
1999;
354
1698-1699
- 274
Zerga M, Cerchetti L, Cicco J, Constantini P, De Riz M.
Desquamative alveolitis: an unusual complication of treatment with Mabthera.
Blood.
1999;
94
271
- 275
Mangel J, Buckstein R, Imrie K et al..
Pulmonary complications after autologous transplantation and immunotherapy with rituximab
in patients with follicular lymphoma [abstract].
Blood.
2000;
96
383a
- 276
Burton C, Kaczmarski R, Jan-Mohamed R.
Interstitial pneumonitis related to rituximab therapy.
N Engl J Med.
2003;
348
2690-2691
- 277
Alexandrescu D T, Dutcher J P, O'Boyle K, Albulak M, Oiseth S, Wiernik P H.
Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.
Leukemia Lymphoma.
2004;
45
2321-2325
- 278
Leon R J, Gonsalvo A, Salas R, Hidalgo N C.
Rituximab-induced acute pulmonary fibrosis.
Mayo Clin Proc.
2004;
79
949-953
- 279
Swords R, Power D, Fay M, O'Donnell R, Murphy P T.
Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura
(ITP).
Am J Hematol.
2004;
77
103-104
- 280
Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T.
A case of interstitial pneumonia induced by rituximab therapy.
Int J Hematol.
2005;
81
169-170
- 281
Speirs A L.
Thalidomide and congenital abnormalities.
Lancet.
1962;
1
303-305
- 282
Carrion Valero F C.
Lung toxicity due to thalidomide.
Arch Bronconeumol.
2003;
39
286
- 283
Diaz Garcia B, de Pablo Gafas A, Ferreiro Alvarez M J.
Lung toxicity due to thalidomide.
Arch Bronconeumol.
2003;
39
240
- 284
Onozawa M, Hashino S, Sogabe S et al..
Thalidomide-induced interstitial pneumonitis.
J Clin Oncol.
2005;
23
2425-2426
- 285
Iguchi T, Sakoda M, Chen C K et al..
Interstitial pneumonia during treatment with thalidomide in a patient with multiple
myeloma.
Rinsho Ketsueki.
2004;
45
1064-1066
- 286
Younis T H, Alam A, Paplham P, Spangenthal E, McCarthy P.
Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.
Br J Haematol.
2003;
121
191-192
- 287
Bennett C L, Schumock G T, Desai A A et al..
Thalidomide-associated deep vein thrombosis and pulmonary embolism.
Am J Med.
2002;
113
603-606
- 288
Steurer M, Sudmeier I, Stauder R, Gastl G.
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide
in combination with darbepoietin-alpha.
Br J Haematol.
2003;
121
101-103
- 289
Warren S, Spencer J.
Radiation reactions in the lung.
AJR Am J Roentgenol.
1940;
43
682-701
- 290
Libshitz H I, Southard M E.
Complications of radiation therapy: The thorax.
Semin Roentgenol.
1974;
9
41-49
- 291
Gross N J.
Pulmonary effects of radiation therapy.
Ann Intern Med.
1977;
86
81-92
- 292
Pagani J J, Libshitz H I.
CT manifestations of radiation-induced change in chest tissue.
J Comput Assist Tomogr.
1982;
6
243-248
- 293
Davis S D, Yankelevitz D F, Henschke C I.
Radiation effects on the lung: clinical features, pathology, and imaging findings.
AJR Am J Roentgenol.
1992;
159
1157-1164
- 294
Movsas B, Raffin T A, Epstein A H, Link C J.
Pulmonary radiation injury.
Chest.
1997;
111
1061-1076
- 295
Logan P M.
Thoracic manifestations of external beam radiotherapy.
AJR Am J Roentgenol.
1998;
171
569-577
- 296
Gibson P G, Bryant D H, Morgan G W et al..
Radiation-induced pneumonitis: a hypersensitivity pneumonitis?.
Ann Intern Med.
1988;
109
288-291
- 297
Jochelson M S, Tarbell N J, Weinstein H J.
Unusual thoracic radiographic findings in children treated for Hodgkin's disease.
J Clin Oncol.
1986;
4
874-882
- 298
Goldman A L, Enquist R.
Hyperacute radiation pneumonitis.
Chest.
1975;
67
613-615
- 299
Loyer E, Fuller L, Libshitz H I, Palmer J L.
Radiographic appearance of the chest following therapy for Hodgkin disease.
Eur J Radiol.
2000;
35
136-148
- 300
Crestanello J A, McGregor C GA, Danielson G K et al..
Mitral and tricuspid valve repair in patients with previous mediastinal radiation
therapy.
Ann Thorac Surg.
2004;
78
826-831
Philippe CamusM.D.
Department of Pulmonary Medicine and Intensive Care, Hopital Le Bocage BP 1542, 21034
Dijon, France
eMail: philippe.camus@chu-dijon.fr
URL: http://www.pneumotox.com
